GlassScriptPhysician profile
Betty Vanvield
NPI 1770048886
$1,412.64
in general payments reported to CMS, 2019-2025
18 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $231 · 2022: $94.97 · 2023: $153 · 2024: $490 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $324.46 | 2022-2024 | Jardiance |
| Novo Nordisk INC | $279.91 | 2021-2024 | |
| Cvrx, INC. | $139.54 | 2025 | Barostim Neo System |
| Actelion Pharmaceuticals US, INC. | $137.99 | 2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $92.74 | 2024-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.53 | 2023-2024 | Lifevest |
| Scpharmaceuticals INC. | $82.19 | 2025 | |
| Abbott Laboratories | $46.59 | 2024-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.21 | 2022 | |
| Esperion Therapeutics, INC. | $29.75 | 2021 | |
| Atricure, INC. | $28.36 | 2024 | |
| Abiomed | $27.50 | 2024 | Impella |
| Amgen INC. | $19.46 | 2022 | |
| Pfizer INC. | $18.31 | 2021 | |
| Lilly USA, LLC | $17.22 | 2023 | Mounjaro |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $16.85 | 2021 | |
| Amarin Pharma, INC. | $13.18 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betty Vanvield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.